McKesson MCK Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Medical-Surgical Solutions | $2.87B+0.5% | $2.99B+1.4% | $2.95B0.0% | $2.7B+2.5% | $2.85B+0.7% | |
| North American Pharmaceutical | $79.12B+2.8% | $88.32B+8.8% | $86.48B+8.1% | $82.73B+24.7% | $76.94B+17.8% | |
| Oncology & Multispecialty | $12.71B+34.8% | $13.01B+37.0% | $12.04B+31.5% | $10.66B+21.4% | $9.43B+23.7% | |
| Prescription Technology Solutions | $1.5B+11.7% | $1.5B+9.4% | $1.38B+8.8% | $1.43B+15.6% | $1.34B+13.5% | |
| Total long-lived assets by Geography | ||||||
| Foreign | $255M-16.7% | $254M— | $261M— | $330M— | $306M-8.4% | |
| United States | $3.18B+10.4% | $3.13B— | $3.1B— | $2.95B— | $2.88B+16.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does McKesson break its business down?
- McKesson (MCK) reports total revenues by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
